Skip to main content

Grafa News and Videos — Page 1626

Latest

Grafa
Technology

LM Funding America reports revenue growth amid Bitcoin volatility and infrastructure expansion

LM Funding America (NASDAQ:LMFA), a cryptocurrency mining and specialty finance company, today announced its financial results for the fourth quarter and full year ended December 31, 2025.

Read more: LM Funding America reports revenue growth amid Bitcoin volatility and infrastructure expansion
Grafa

BioXcel Therapeutics advances toward home-use approval for IGALMI following 2025 financial results

BioXcel Therapeutics (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the fourth quarter and full year ended December 31, 2025.

Read more: BioXcel Therapeutics advances toward home-use approval for IGALMI following 2025 financial results
Grafa

Instil Bio shifts to external innovation strategy following discontinuation of lead asset

Instil Bio (NASDAQ:TIL), a clinical-stage biopharmaceutical company, today reported its financial results for the fourth quarter and full year ended December 31, 2025, while outlining a transformative shift in its corporate strategy.

Read more: Instil Bio shifts to external innovation strategy following discontinuation of lead asset
Grafa

AstraZeneca’s Tozorakimab delivers milestone Phase III victory in broad COPD population

AstraZeneca (NASDAQ:AZN) today announced positive high-level results from the OBERON and TITANIA Phase III trials, marking a historic milestone in the treatment of chronic obstructive pulmonary disease (COPD).

Read more: AstraZeneca’s Tozorakimab delivers milestone Phase III victory in broad COPD population
Grafa
Technology

Legence shares soar as 2025 revenue hits $2.5B on surging decarbonization demand

Legence (NASDAQ:LGN), a preeminent integrated provider of energy efficiency and sustainability solutions for the built environment, today reported record-breaking financial results for the fourth quarter and full year ended December 31, 2025.

Read more: Legence shares soar as 2025 revenue hits $2.5B on surging decarbonization demand
Grafa
Health

SBC Medical Group reports 117% surge in Q4 net income despite revenue headwinds

SBC Medical Group Holdings (NASDAQ:SBC), a leading Management Services Organization (MSO) for a diverse range of medical franchises, today announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025.

Read more: SBC Medical Group reports 117% surge in Q4 net income despite revenue headwinds
Grafa

FDA approves Novo Nordisk’s Awiqli as first once-weekly basal insulin for type 2 diabetes

Novo Nordisk (NYSE:NVO) today announced that the U.S. Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae), the first and only once-weekly, long-acting basal insulin for adults living with type 2 diabetes.

Read more: FDA approves Novo Nordisk’s Awiqli as first once-weekly basal insulin for type 2 diabetes

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift